Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. | For the biotech formerly ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...

Real Chemistry has partnered with Corval to add a commercialization planning and launch platform to its offering. The ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Lucid is planning on bringing #CheckYourFoodTube events to more ex-NFL stars in cities across the U.S., with a goal of ...

Under the new cooperation deal, Recipharm gets access to Exela’s manufacturing plant in Lenoir, North Carolina. Exela is ...